Status:
COMPLETED
Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease Subjects
Lead Sponsor:
Pfizer
Conditions:
Chronic Kidney Disease
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
This study is being conducted to evaluate sitaxsentan dosing in subjects with chronic kidney disease.
Eligibility Criteria
Inclusion
- Has stage 1-5 chronic kidney disease (CKD) as defined by the Kidney Disease Outcomes Quality Initiative (K/DOQI) with proteinuria, including any of the following aetiologies: immunoglobulin (IgA) nephropathy, polycystic kidney disease (PCKD), congenital abnormalities, reflux nephropathy, focal segmental glomerulosclerosis, minimal change nephropathy, and membranous nephropathy.
Exclusion
- Required peritoneal dialysis or haemodialysis.
- Has kidney disease due to diabetes mellitus, vasculitis, systemic lupus erythematosus, or known renovascular disease; antiglomerular basement membrane disease; or is on immunosuppressive medication.
Key Trial Info
Start Date :
May 9 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 6 2009
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT00810732
Start Date
May 9 2007
End Date
March 6 2009
Last Update
July 6 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Research Centre and Pharmacology Unit
Edinburgh, Scotland, United Kingdom, EH4 2XU
2
the University of Edinburgh, Western General Hospital, Department of Medical Sciences
Edinburgh, Scotland, United Kingdom, EH4 2XU